Trinity Financial Advisors LLC Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)

Trinity Financial Advisors LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 3.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,704 shares of the company’s stock after selling 86 shares during the quarter. Trinity Financial Advisors LLC’s holdings in Johnson & Johnson were worth $389,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Sugarloaf Wealth Management LLC raised its position in Johnson & Johnson by 2.0% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 6,505 shares of the company’s stock valued at $941,000 after purchasing an additional 127 shares in the last quarter. HBW Advisory Services LLC increased its stake in shares of Johnson & Johnson by 2.2% during the fourth quarter. HBW Advisory Services LLC now owns 6,534 shares of the company’s stock worth $945,000 after buying an additional 141 shares during the period. Jacobs & Co. CA raised its holdings in Johnson & Johnson by 0.3% in the fourth quarter. Jacobs & Co. CA now owns 56,569 shares of the company’s stock valued at $8,181,000 after acquiring an additional 179 shares in the last quarter. Sage Capital Advisors llc grew its holdings in Johnson & Johnson by 0.5% during the 4th quarter. Sage Capital Advisors llc now owns 43,731 shares of the company’s stock worth $6,324,000 after acquiring an additional 230 shares in the last quarter. Finally, Harbor Capital Advisors Inc. increased its position in shares of Johnson & Johnson by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,879 shares of the company’s stock valued at $7,214,000 after purchasing an additional 1,224 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on JNJ shares. Royal Bank of Canada boosted their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Bank of America restated a “neutral” rating and set a $166.00 target price on shares of Johnson & Johnson in a research note on Tuesday, December 10th. Wells Fargo & Company increased their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Morgan Stanley upped their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $174.71.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ stock traded down $0.20 during trading on Friday, hitting $142.07. The company had a trading volume of 8,585,174 shares, compared to its average volume of 7,666,985. The firm has a 50-day moving average price of $150.03 and a 200-day moving average price of $156.04. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a market cap of $342.05 billion, a PE ratio of 20.56, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same period last year, the firm posted $2.66 EPS. Johnson & Johnson’s quarterly revenue was up 5.2% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.49%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.